These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23098788)

  • 1. [Androgen deprivation therapy for prostate cancer and osteoporotic risk].
    Cortet B; Lartigau E; Caty A; Moulinier F; Staerman F; Villamizar-Vesga J; Villers A
    Prog Urol; 2012 Sep; 22 Suppl 2():S31-8. PubMed ID: 23098788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Metabolic impact of androgen deprivation therapy for prostate cancer].
    Andrès E; Eschwege P; Lang H; Moreau JL; Peiffert D; Thiery-Vuillemin A; Kleinclauss F
    Prog Urol; 2012 Sep; 22 Suppl 2():S39-47. PubMed ID: 23098789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fracture risk assessment tool score to bone mineral density for estimating fracture risk in patients with advanced prostate cancer on androgen deprivation therapy.
    James H; Aleksic I; Bienz MN; Pieczonka C; Iannotta P; Albala D; Mariados N; Mouraviev V; Saad F
    Urology; 2014 Jul; 84(1):164-8. PubMed ID: 24976229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving bone health in prostate cancer patients starting androgen deprivation therapy: does Fracture Risk Assessment Tool (FRAX®) enhance stratification and targeted management?
    Sharqawi A; Hewitt K; Alexander C; El-Sakka AI; Lee L
    Arch Osteoporos; 2022 Nov; 17(1):143. PubMed ID: 36376762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Osteoporosis in men].
    Biver E; Uebelhart B
    Rev Med Suisse; 2013 Jun; 9(390):1260-4. PubMed ID: 23821844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone loss in men under androgen-deprivation therapy for prostate cancer].
    Ishizaka K; Machida T; Yoshida K
    Nihon Rinsho; 2005 Apr; 63(4):721-6. PubMed ID: 15828242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N; Huynh CC; Rashid P
    Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment effect of breast cancer and prostate cancer on bone].
    Varsavsky M; Guadalix Iglesias S
    Med Clin (Barc); 2013 Feb; 140(4):164-8. PubMed ID: 22841464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.
    Smith MR
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):21-5. PubMed ID: 15202584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone health management in men undergoing ADT: examining enablers and barriers to care.
    Damji AN; Bies K; Alibhai SM; Jones JM
    Osteoporos Int; 2015 Mar; 26(3):951-9. PubMed ID: 25526712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone loss in prostate cancer: evaluation, treatment and prevention.
    Saad F
    Can J Urol; 2005 Feb; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T
    Cancer; 2005 Jan; 103(2):237-41. PubMed ID: 15597384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GU radiation oncologists consensus on bone loss from androgen deprivation.
    Duncan GG; Corbett T; Lukka H; Warde P; Pickles T
    Can J Urol; 2006 Feb; 13(1):2962-6. PubMed ID: 16515750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.